Amentum Stock Drops on Expected Winding Down of Government Programs
Amentum Holdings swung to a fourth-quarter profit but shares sank Tuesday when executives said in the company's earnings call that they see fiscal 2025 growth being affected by an expected winding dow
International, domestic insurers push into catastrophe-hit US property markets
LONDON (Reuters) -International and domestic insurers are pushing into the U.S. market for hard-to-protect homes, charging high premiums and enjoying strong profits after some U.S. firms pulled out. T
Market Breadth Worsens As Tech Giants Break Free From S&P 500 Reality: Is This Bullish Or Bearish For 2025?
The performance gap between the cap-weighted S&P 500 — tracked by the SPDR S&P 500 ETF Trust (NYSE:SPY) — and its equal-weighted sibling, the Invesco S&P 500 Equal Weight ETF (NYSE:RSP), has blown
The Dow drops 245 points as it heads for its longest losing streak in decades
The Dow Jones Industrial Average fell almost 250 points on Tuesday in what could be its longest losing streak since the 1970s.
Weis Markets acquires Saylor’s Market
The grocer, however, will close an underperforming store
Tesla Stock Touches Another Record High
Tesla shares hit another record high Tuesday after an analyst upgraded their rating of the electric vehicle maker to above $500.
Quantum Computing Stock Skyrockets Further on NASA Contract
Quantum Computing was awarded a contract by NASA's Goddard Space Flight Center to use its entropy quantum optimization machine to help the space agency's imaging.
Nvidia stock slumps into a correction and Broadcom sinks despite its 'Nvidia moment'
Nvidia (NVDA) stock is in correction territory, and rival chipmaker Broadcom’s (AVGO) late-year boost took a hit Tuesday morning.
Viridian Therapeutics sees stock soar after Phase III TED success
The company’s chronic thyroid eye disease treatment, veligrotug, was able to reduce eye bulge by 56% compared with placebo.
Pfizer Stock Rises as 2025 Outlook in Line With Expectations
Pfizer shares rose Tuesday morning after the pharmaceutical company affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.